An Overview on Antifungal Drug Therapy
DOI:
https://doi.org/10.22270/ajprd.v11i3.1270Keywords:
Antifungal, Candidiasis, Fungal Infections,Cutaneous Candidiasis,Athlete’s FootAbstract
Nowadays, the majority of fungal infections, including candidiasis, can cause anything from a minor mucous membrane infection to fatal systemic mycoses. Due to the most rapid increase in populations with impaired hosts, such as those with HIV/AIDS, organ transplant recipients, and chemotherapy patients, candida infections present a serious clinical challenge internationally. In addition, a dramatic rise in the number of elderly people who are vulnerable to fungal infections is anticipated in the next decades. Due to the eukaryotic structure of the cells, developing antifungal medications for these issues is more challenging than developing antibacterial medications. Therefore, there are now only a limited number of antifungal medications available to treat the wide range of fungal infections. Additionally, the antifungal arsenal against fungal diseases has been constrained by the rise in antifungal resistance and unfavourable host effects.
Downloads
References
2. McKeny, Patrick T.; Nessel, Trevor A.; Zito, Patrick M., "Antifungal Antibiotics", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 30844195, retrieved 2022-04-23
3. Scorzoni, Liliana; de Paula e Silva, Ana C. A.; Marcos, Caroline M.; Assato, Patrícia A.; de Melo, Wanessa C. M. A.; de Oliveira, Haroldo C.; Costa-Orlandi, Caroline B.; Mendes-Giannini, Maria J. S.; Fusco-Almeida, Ana M. (2017). "Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis". Frontiers in Microbiology. 8: 36. doi:10.3389/fmicb.2017.00036. ISSN 1664-302X. PMC 5253656. PMID 28167935.
4. Kelemen, H.; Orgovan, G.; Szekely-Szentmiklosi, B. "[The pharmaceutical chemistry of azole antifungals.]". Acta Pharmaceutica Hungarica.2016; 86 (3): 85–98. ISSN 0001-6659. PMID 29489080.
5. Benitez, Lydia L.; Carver, Peggy L. "Adverse Effects Associated with Long-Term Administration of Azole Antifungal Agents". Drugs. 2019; 79 (8): 833–853. doi:10.1007/s40265-019-01127-8. ISSN 1179-1950. PMID 31093949. S2CID 155093431. "Azole - an overview | ScienceDirect Topics". www.sciencedirect.com. Retrieved 2022-04-23.
6. Nocua-Báez, Laura Cristina; Uribe-Jerez, Paula; Tarazona-Guaranga, Leonardo; Robles, Ricardo; Cortés, Jorge A.; Nocua-Báez, Laura Cristina; Uribe-Jerez, Paula; Tarazona-Guaranga, Leonardo; Robles, Ricardo; Cortés, Jorge A. "Azoles of then and now: a review". Revistachilena de infectología. 2020; 37(3): 219–230. doi:10.4067/s0716-10182020000300219. ISSN 0716-1018. PMID 32853312. S2CID 225580512.
7. Prasad, Rajendra; Shah, Abdul Haseeb; Rawal, Manpreet Kaur , Ramos, José; Sychrová, Hana; Kschischo, Maik (eds.), "Antifungals: Mechanism of Action and Drug Resistance", Yeast Membrane Transport, Cham: Springer International Publishing, 2016; 892: 327–349, doi:10.1007/978-3-319-25304-6_14, ISBN 978-3-319-25304-6, PMID 26721281, retrieved 2022-04-23
8. Johnson, Melissa D. "Antifungals in Clinical Use and the Pipeline". Infectious Disease Clinics of North America. Fungal Infections. 2021; 35(2): 341–371. doi: 10.1016/j.idc.2021.03.005. ISSN 0891-5520. PMID 34016281. S2CID 235074214.
9. Antifungal Combinations against Candida Species: From Bench to Bedside.Fioriti S, Brescini L, Pallotta F, Canovari B, Morroni G, Barchiesi F.J Fungi (Basel). 2022 Oct 13; 8(10):1077
10. Pfaller, M.A. et al. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary Resistance using national committee for clinical laboratory standards Susceptibility testing methods. Antimicrob. Agents Chemother.2002; 46,3518–3521
11. Pfaller MA, Diekma DJ. Rare and emerging opportunistic fungal patho-Gens: concern for resistance beyond Candida albicans and AspergillusFumigatus. J Clin Microbiol 2004; 42: 4419-4431.
12. Pristov, K. E. &Ghannoum, M. A. Resistance of Candida to azoles and echinocandins worldwide. Clin. Microbiol. Infect. 25, 792–798 (2019).
13. Pianalto K., Alspaugh J.A. New Horizons in Antifungal Therapy. J. Fungi. 2016; 2:26. doi: 10.3390/jof2040026.
14. Brown G.D., Denning D.W., Gow N., Levitz S.M., Netea M., White T.C. Hidden Killers: Human Fungal Infections. Sci. Transl. Med. 2012; 4:165rv13. doi: 10.1126/scitranslmed.3004404.
15. Shapiro RS, Robbins N, Cowen LE. 2011. Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev 75:213–267.
Published
How to Cite
Issue
Section
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.